Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.

Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.

Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.

Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.

Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.

Abstract: The present invention relates to pharmaceutical combinations therapies based on p38 kinase inhibitors and another active ingredient, pharmaceutical compositions comprising such combinations, processes for preparing them and their use in the treatment of cytokine mediated diseases.

Abstract: A batch fluid bed processing machine for processing products. The batch fluid bed processing machine has a container and a gas source coupled to a first end of the container. An expansion chamber is coupled to a second end of the container. An expansion funnel having a second open end is coupled to an interface between the expansion chamber and the container. A column is mounted in the container between the expansion funnel and the gas source. A gas stream is passed from the gas source and through the container. Products may be coated or dryed in the gas stream.

Abstract: Compaction of mexiletine hydrochloride crystals is described, which provides a powder suitable for use in capsules without use of organic solvents.

Abstract: Disclosed are formulations and compositions comprising, and process for preparing, improved parenteral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea. Also disclosed are methods of treating cytokine mediated diseases using such formulations and compositions.

Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.

Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.

Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.

Abstract: A process for separating particles of a cohesive form of a polydisperse compound or composition comprising nevirapine, nevirapine hemihydrate, mexiletine or mexiletine hydrochloride according to size is disclosed which comprises milling and sizing the particles in an apparatus which includes individual and/or nested sieves each of which may also include a quantity of beads, disks and/or other geometric or non-geometric shapes. The sieves can be rotated, vibrated or agitated in any and all combinations by various methods to achieve independently horizontal rotation and vertical reciprocation (similar to a merry-go-round) to efficiently segregate, size or mill cohesive and polydisperse powder particles to specific size ranges. The invention also contemplates a method for using the apparatus in the sizing and quantification of aggregated particles of cohesive disperse powders.

Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.

Abstract: Milling/sizing apparatus which includes individual and/or nested sieves each of which may also include a quantity of beads, disks and/or other geometric or non-geometric shapes. The sieves can be rotated, vibrated or agitated in any and all combinations by various methods to achieve independently horizontal rotation and vertical reciprocation (similar to a merry-go-round) to efficiently segregate, size or mill cohesive and polydisperse powder particles to specific size ranges. The invention also contemplates a method for using the apparatus in the sizing and quantification of aggregated particles of cohesive disperse powders.